

Rapid. Reliable. Remarkable. Resourceful

Antibody Discovery Powered by PUREfrex® and iBody Inc.

ioin our free webinar!





Takashi Ebihara
COO
GeneFrontier Corporation





Shin Kawano Senior Scientist iBody,Inc.

Rapid. Reliable. Remarkable. Resourceful: Antibody Discovery Powered by PUREfrex® and iBody Inc.

Oct 15th (Wed), 4-5pm PDT, 7-8pm EDT

Session 1:

Empowering Discovery: PUREfrex® Tools for High-Throughput Cell-Free Expression and In Vitro Display



GeneFrontier introduces its flagship cell-free protein synthesis system, PUREfrex®, designed to accelerate protein expression workflows with unmatched flexibility and scalability. This session will highlight how PUREfrex® supports high-throughput applications, including mRNA/ribosome display and other in vitro display technologies, enabling rapid screening and selection of functional proteins and antibodies. Attendees will gain insights into the latest reagent offerings, technical capabilities, and integration strategies for AI/ML-driven drug discovery platforms.

Session 2:

Ultra-Comprehensive and Rapid Antibody Screening:
The Fusion of Single-Cell Technology and Cell-Free Expression Systems

iBody will introduce its proprietary platform that enables the discovery of highly functional antibodies against challenging targets.

Built on single B cell screening and powered by PUREfrex® expression, iBody delivers high-affinity, high-specificity antibodies in a short timeframe. In this session, we will present our highly effective antibody discovery process and explain how it achieves superior affinity and specificity while preserving native antibody diversity. This approach enables the identification of antibodies against difficult targets such as small molecules, post-translational modifications, and therapeutic antibodies.





Registration is required (free of charge).

https://x.gd/FGhCg

(Organizer) Body Inc.

Nagoya Life Science Incubator (NALIC) #417 2-22-8, Chikusa, Chikusa-ku Nagoya 464-0858, Jap.